Aion Therapeutic Inc.
ANTCF
$0.0055
-$0.001-15.39%
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -19.84% | 196.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.84% | 196.27% | |||
| Cost of Revenue | -0.28% | 63.85% | |||
| Gross Profit | -44.23% | 35,425.00% | |||
| SG&A Expenses | 26.91% | 1.98% | |||
| Depreciation & Amortization | 0.00% | 4.50% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.91% | 16.57% | |||
| Operating Income | -70.13% | 37.95% | |||
| Income Before Tax | -57.61% | 93.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.61% | 93.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.61% | 93.19% | |||
| EBIT | -70.13% | 37.95% | |||
| EBITDA | -71.70% | 38.04% | |||
| EPS Basic | -50.00% | 93.88% | |||
| Normalized Basic EPS | -50.00% | 33.33% | |||
| EPS Diluted | -50.00% | 93.88% | |||
| Normalized Diluted EPS | -50.00% | 33.33% | |||
| Average Basic Shares Outstanding | 7.01% | 11.19% | |||
| Average Diluted Shares Outstanding | 7.01% | 11.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
